Localized nanomedicine for urologic cancers: anatomy-guided design and clinical translation.

Bladder, prostate, and renal cancers differ in their anatomical locations, tissue structures, and routes of clinical intervention. Conventional systemic treatments are often limited by nonspecific biodistribution, insufficient tumor accumulation, and toxicity. Localized nanomedicine delivery offers an alternative strategy by using organ-specific anatomical access to increase exposure at the tumor site and reduce systemic distribution. Its success depends on the compatibility of nanomedicine delivery systems with the physiological environment, anatomical characteristics, and procedural requirements of the organ. Here, we compare local nanomedicine strategies for these three cancers and discuss how anatomy can guide their design. We therefore define five design criteria for localized nanomedicines: retention, penetration, responsiveness, targeting, and synergy. For each criterion, describe relevant engineering approaches and applications in individual cancers. We also consider barriers to clinical use, including formulation reproducibility and compatibility with clinical workflows. An approach that combines anatomy, nanomedicine design, and delivery procedures may support their clinical translation for more precise diagnosis and treatment.